Technical Analysis for NTRA - Natera, Inc.

Grade Last Price % Change Price Change
grade A 38.19 3.05% 1.13
NTRA closed up 3.05 percent on Monday, October 14, 2019, on approximately normal volume. The bulls were able to push the stock to a new 52-week high. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical NTRA trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
New 52 Week High Strength 0.00%
Stochastic Reached Overbought Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
New 52 Week Closing High Bullish 3.05%

Older signals for NTRA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Natera, Inc., a genetic testing company, develops and commercializes non-invasive methods for analyzing deoxyribonucleic acid (DNA) in the United States and Europe. The company primarily offers Panorama, a non-invasive prenatal test for fetal chromosomal abnormalities; Horizon test; and pre-implantation genetic screening and pre-implantation genetic diagnosis tests under the Spectrum brand to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization. It also provides products of conception testing under the Anora brand to analyze fetal chromosomes to understand the cause of miscarriage; non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal DNA in a pregnant mother's blood and a blood sample from the alleged father; and high throughput carrier screening to determine the risk of passing severe genetic diseases on to offspring. Natera sells its tests directly and partner with other clinical laboratories to distribute its tests. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Medicine Clinical Medicine Medical Genetics Medical Tests Applied Genetics DNA Genetic Testing DNA Paternity Testing In Vitro Fertilization Severe Genetic Diseases
Is NTRA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 38.87
52 Week Low 11.08
Average Volume 656,834
200-Day Moving Average 23.0769
50-Day Moving Average 32.0866
20-Day Moving Average 34.282
10-Day Moving Average 35.048
Average True Range 1.8573
ADX 20.73
+DI 33.1411
-DI 15.792
Chandelier Exit (Long, 3 ATRs ) 33.2981
Chandelier Exit (Short, 3 ATRs ) 37.0919
Upper Bollinger Band 37.5438
Lower Bollinger Band 31.0202
Percent B (%b) 1.1
BandWidth 19.029228
MACD Line 1.3033
MACD Signal Line 1.0022
MACD Histogram 0.3011
Fundamentals Value
Market Cap 2.03 Billion
Num Shares 53.2 Million
EPS -2.43
Price-to-Earnings (P/E) Ratio -15.72
Price-to-Sales 2.91
Price-to-Book 11.62
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 40.97
Resistance 3 (R3) 40.88 39.88 40.50
Resistance 2 (R2) 39.88 39.17 39.92 40.35
Resistance 1 (R1) 39.03 38.73 39.46 39.12 40.19
Pivot Point 38.03 38.03 38.24 38.07 38.03
Support 1 (S1) 37.18 37.32 37.61 37.27 36.19
Support 2 (S2) 36.18 36.88 36.22 36.03
Support 3 (S3) 35.33 36.18 35.88
Support 4 (S4) 35.42